title: Pharmacological onomastics: what's in a name?
abstract: Drugs are named for their primary receptor target and overt action (agonism, antagonism) but the observation of multiple or collateral efficacies emanating from drugs activating a single receptor target is posing a challenge for drug classification and nomenclature. With increasing abilities to detect alteration in cellular function has come the identification of efficacies that are not necessarily manifest in obvious changes in cell response. Specifically, some agonists selectively activate cellular pathways, demonstrate phenotypic behaviour associated with cell type and some antagonists actively induce receptor internalization without activation. In addition, the effects of allosteric modulators can be linked to the nature of the co-binding ligand posing a similar complication in classification and naming. Thus, accurate labels for this new generation of selective drugs may require identification of receptor partners (G-protein type, beta-arrestin) or pathway or, in the case of allosteric modulators, identification of co-binding ligands. The association of distinct phenotypic behaviours with molecules opens the opportunity to better associate clinical effects with distinct pharmacological properties.
authors: Biochemical and Cellular Targets, GlaxoSmithKline Research and Development, Research Triangle Park, NC 27709, USA. Terry.P.Kenakin@gsk.com
authors: T P
authors: TP
authors: Kenakin
mesh_terms: D000494:Allosteric Regulation; D054313:Drug Agonism; D004336:Drug Antagonism; D016503:Drug Delivery Systems / Q000145:classification*; D006801:Humans; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000145:classification*; D009626:Terminology as Topic
chemical_list: D008024:Ligands; D004364:Pharmaceutical Preparations
references: Mol Pharmacol. 2000 Dec;58(6):1230-8
references: 11093758
references: Trends Pharmacol Sci. 1995 Jul;16(7):232-8
references: 7667897
references: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11406-11
references: 13679574
references: EMBO J. 2004 Oct 13;23(20):3950-61
references: 15385966
references: Clin Sci (Lond). 2007 Feb;112(4):217-27
references: 17223795
references: Br J Pharmacol. 2007 Jul;151(6):851-9
references: 17533422
references: Annu Rev Pharmacol Toxicol. 2002;42:349-79
references: 11807176
references: Trends Pharmacol Sci. 1995 Aug;16(8):256-8
references: 7482982
references: Mol Pharmacol. 2005 Jun;67(6):2016-24
references: 15749995
references: J Biol Chem. 2001 Jul 27;276(30):28083-91
references: 11323408
references: Mol Pharmacol. 2007 Feb;71(2):549-57
references: 17090705
references: Trends Pharmacol Sci. 2006 Jan;27(1):41-7
references: 16310864
references: Int J Neuropsychopharmacol. 2000 Dec;3(4):339-349
references: 11343614
references: Mol Pharmacol. 1997 Jul;52(1):172-9
references: 9224827
references: Trends Pharmacol Sci. 2002 Jun;23(6):275-80
references: 12084633
references: J Biol Chem. 1995 Nov 24;270(47):28268-75
references: 7499324
references: Mol Pharmacol. 2005 Apr;67(4):1268-82
references: 15644495
references: Trends Pharmacol Sci. 2004 Aug;25(8):413-22
references: 15276710
references: J Biol Chem. 2006 Apr 21;281(16):10856-64
references: 16492667
references: Mol Pharmacol. 1988 Dec;34(6):744-54
references: 2849042
references: FASEB J. 2001 Mar;15(3):598-611
references: 11259378
references: Nat Rev Neurosci. 2001 Apr;2(4):274-86
references: 11283750
references: J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
references: 16803859
references: Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6802-7
references: 8692899
references: J Mol Neurosci. 2005;26(2-3):253-64
references: 16012199
references: Mol Pharmacol. 2003 Dec;64(6):1357-69
references: 14645666
references: J Biol Chem. 2004 Jan 2;279(1):686-91
references: 14559905
references: Mol Pharmacol. 2006 Nov;70(5):1575-84
references: 16901982
references: Brain Res. 1998 Apr 27;791(1-2):167-76
references: 9593876
references: Mol Pharmacol. 1996 Sep;50(3):662-9
references: 8794908
references: Ann N Y Acad Sci. 1997 May 30;812:98-115
references: 9508759
references: Expert Opin Drug Discov. 2006 Dec;1(7):635-52
references: 23495990
references: Mol Pharmacol. 2004 Jan;65(1):2-11
references: 14722230
references: Trends Pharmacol Sci. 1997 Dec;18(12):468-74
references: 9458695
references: Neuroscience. 1999;91(2):599-606
references: 10366017
references: Psychoneuroendocrinology. 2001 Oct;26(7):649-55
references: 11500247
references: Science. 2005 Apr 22;308(5721):512-7
references: 15845844
references: J Pharmacol Exp Ther. 2001 Dec;299(3):1066-72
references: 11714896
references: Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):180-90
references: 17237844
references: J Recept Signal Transduct Res. 2006;26(1-2):107-28
references: 16595341
references: J Biol Chem. 2003 Jan 10;278(2):896-907
references: 12417595
references: Cell Signal. 2006 Nov;18(11):1815-33
references: 16750901
references: J Biol Chem. 2001 Sep 14;276(37):34853-61
references: 11459843
references: Science. 2006 Apr 14;312(5771):217-24
references: 16614209
references: Nat Methods. 2006 Mar;3(3):165-74
references: 16489332
references: Brain Res Bull. 2001 Nov 15;56(5):441-51
references: 11750789
references: Mol Cell. 2006 Dec 8;24(5):643-52
references: 17157248
references: Proc Natl Acad Sci U S A. 1989 Oct;86(19):7321-5
references: 2552439
references: J Biol Chem. 2001 Jul 6;276(27):24433-6
references: 11320077
references: J Biol Chem. 2001 Mar 16;276(11):8269-77
references: 11069907
references: Biotechnol Lett. 2006 Dec;28(24):1971-82
references: 17021660
references: Br J Pharmacol Chemother. 1956 Dec;11(4):379-93
references: 13383117